PATHWAY PROFILING ANTIBODIES & REAGENTS
     
Products
Product : Recombinant Protein >> B7.1-Fc Purified Recombinant Protein
Back  >   Printable Version  >  Download in PDF  > 
B7.1-Fc Purified Recombinant Protein
 
Cat. No.DescriptionFormatUnitPrice(USD)QuantityBulk Quotation
IMR-279-0050
B7.1-Fc Purified Recombinant ProteinProtein
0.05 mg
--
     
Catalog No
 : IMR-279-0050
Description
B7.1 is a transmembrane protein belonging to a family of costimulatory molecules expressed on the surface of antigen presenting cells (APCs). Binding of B7.1 to the T cell costimulatory receptors, CD28 and CTLA-4, is essential for the activation and regulation of T cell immunity. Mice deficient in B7.1 and B7.2 have profound deficits in both humoral immune responses (antibody production) and cellular immune responses. Soluble B7.1-Fc fusion protein can bind to human and murine T cells and stimulate their proliferation. Recently, B7.1-Fc fusion protein alone or in combination with anti-CD4+ or CD25+ depletion (depletion of Tregs) has been used in animal models to inhibit tumor growth.
Formulation
50 ug in 25 ul of phosphate-buffered solution, pH 7.2, containing no preservative. 0.2 um filter sterilized.
Stability
Aliquot and store at -70°C or colder. Avoid freeze-thaw steps.
Purity

Protein A Chromatography
Amino Acid Sequence

MW: approximately 66 kD

MGHTRRQGTSPSKCPYLNFFQLLVLAGLSHFCSGVIHVTKEVKEVATL

SCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDI

TNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVTLSVKADFPT

PSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEELNAINTTVSQDPETEL

YAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFPDDKTHT

CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV

DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI

AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM

HEALHNHYTQKSLSLSPGK


Extracellular domain (amino acids 1-241) of human B7.1 sequence is underlined.

Human Fc sequence is in italics.
Endotoxin
Endotoxin level < 0.1 EU/ug of the protein (< 0.01 ng/ug of the protein) as determined by the LAL test.
Usage
Can be used as an effective anti-tumor agent in combinantion with Treg depletion. May block binding of membrane bound B7.1 with its receptors, CD28 and CTLA-4, thereby sustaining the activation of tumor specific T cells or preventing their down regulation.
   

Figure 1. SDS-PAGE analysis of recombinant B7.1-Fc to demonstrate purity of protein.

 

Figure 2. Effect of B7.1-Fc on the growth of tumor cells. B7.1-Fc fusion protein protein prevents growth of a mouse solid tumor, RENCA. The immunotherapy is more more effective in combination with CD25+ depletion and B7.1-Fc fusion protein. (Adapted from Liu et al, Clin Cancer Res 11 (23): 8492-8502 (2005)

 

Figure 3. B7.1-Fc treatment alone or in combination with anti-CD4+ or anti-CD25+ depletion was found to induce tumor regression in mice.

Research purposes only. Not for diagnostic or in vivo use.

Products

Services

Resources

Purchasing

Company

© IMGENEX Corporation
Toll Free: 1-888-723-4363
Phone: 1-858-642-0978
Fax: 1-858-642-0937 Email: info@imgenex.com

All products are For Research Use Only, unless indicated otherwise. Not for use in diagnostic or therapeutic procedures.

  • What's New
  • Reporter Cells
  • Screening Services
  • Interactive Pathways